Independent. No paid placement. Reviewed weekly Editorial policy Newsletter

Home›The Library›Ecallantide

Ecallantide

Written by The Peptide Record editorialClinical review not yet completedLast reviewed 15 September 2026

Ecallantide (Kalbitor) is a real, FDA-approved recombinant protein for acute hereditary angioedema attacks — a direct comparison to this site's icatibant page, since both treat the same condition by different mechanisms, but ecallantide's own anaphylaxis risk means it can only be given by a healthcare professional.

On this page
  1. Upstream of icatibant, not downstream
  2. The approval and EDEMA trials
  3. The boxed warning that shapes how it's used
  4. Current status

In brief

Should you care? Relevant if you or someone you know has hereditary angioedema and is comparing acute-attack treatment options.

The short version

  • Blocks plasma kallikrein, upstream in the same pathway that icatibant blocks downstream at the receptor.
  • Approved December 2009 for acute HAE attacks, based on the EDEMA trial program.
  • Must be given by a healthcare professional — unlike icatibant, which can be self-administered — because ecallantide itself carries a real anaphylaxis risk.

Upstream of icatibant, not downstream

Ecallantide is a 60-amino-acid recombinant protein that inhibits plasma kallikrein, blocking the conversion of a precursor molecule into bradykinin — acting upstream in the same biochemical cascade that drives hereditary angioedema (HAE) attacks. This site's icatibant page covers a drug that treats the same condition from the opposite direction: icatibant is a synthetic decapeptide that blocks the bradykinin B2 receptor directly, acting downstream at the point where bradykinin would otherwise cause swelling. Both approaches limit the same underlying effect; they just intervene at different steps.

The approval and EDEMA trials

The FDA approved ecallantide (as Kalbitor) on 1 December 2009 for acute HAE attacks, originally in patients 16 and older (the current label covers ages 12 and up). It was developed by Dyax Corp and is now marketed by Takeda. The approval rested on the EDEMA trial program, including EDEMA4 (Levy et al., Ann Allergy Asthma Immunol 2010, PMID 20568386), a phase 3, double-blind, placebo-controlled trial that found a statistically significant improvement in symptom scores four hours after a single 30mg subcutaneous dose compared to placebo.

The boxed warning that shapes how it's used

Ecallantide carries a boxed warning for anaphylaxis: in clinical trials, anaphylaxis occurred in roughly 4% of HAE patients treated with the drug (10 of 255 patients). Because of that risk, the label requires ecallantide to be administered only by a healthcare professional with appropriate medical support for anaphylaxis on hand — the key practical, day-to-day difference from icatibant, which can be self-administered at home after training. For a patient choosing between the two, that administration requirement is often the deciding practical factor.

Current status

Still marketed by Takeda; no generic or biosimilar identified. Hospital/clinic-administered biologic for a rare genetic disease, with no wellness or grey-market presence.

References

  1. Levy RJ, Lumry WR, McNeil DL, et al., "EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema," Ann Allergy Asthma Immunol 2010;104(6):523-529, PMID 20568386.
  2. FDA approval history for Kalbitor (ecallantide), 1 December 2009.